Subakut Sklerozan Panensefalitli Hastaların Plazmasında Aprepitant Tayini İçin Hassas ve Hızlı Bir LC-MS Yönteminin Geliştirilmesi

Yıl 2025, Cilt: 25 Sayı: 6, 1301 - 1307

Filiz Arıöz , Gizem Kunal Şalli , Songul Tezcan , Emine Arman Kandırmaz , Mesut Sancar , Bahadır Konuşkan , İbrahim Halil Öncel , Banu Anlar

Öz

Bu çalışmada, Subakut Sklerozan Panensefalit (SSPE) hastalarının kanındaki aprepitant düzeylerinin rutin olarak izlenmesi için hassas, seçici, hızlı ve doğrulanmış bir Sıvı Kromatografisi-Kütle Spektrometrisi (LC-MS) yöntemi geliştirilmiştir. Geliştirilen bu yöntem, SSPE hastalarında ilaca bağlı potansiyel toksisitenin tespit edilmesi ve izlenmesinde etkili bir şekilde kullanılmıştır. Aprepitant, insan plazmasından sıvı-sıvı ekstraksiyonu yöntemi kullanılarak ekstrakta edilmiştir. Kromatografik analiz için en uygun koşullar, C18 (50 mm x 2,1 mm x 3 µm) kolonu, asetonitril/su (50/50 (%0,2 formik asit) v/v) izokrotik mobil fazı ve 0,40 mL/dakika akış hızı olarak bulunmuştur. Kütle spektrometresinde, pozitif modda, elektrosprey iyonizasyon tekniği ile çalışılmış ve aprepitant 535.20 m/z değerinde tespit edilmiştir. Aprepitant için alıkonma zamanı 2,70 dakika, toplam analiz süresi 4,8 dakika, doğrusal konsantrasyon aralığı 0,0125-3,00 µg/mL (r=0,9976), LOD ve LOQ değerleri sırasıyla 0,01 μg/mL ve 0,03 μg/mL olarak bulunmuştur. Geliştirilen yöntem, SSPE hastalarından alınan plazma örneklerinde aprepitantın konsantrasyonunun tespiti için başarıyla kullanılmıştır. Geliştirilen ve valide edilen bu yöntem seçici, duyarlı ve hızlı bir yöntemdir. Preklinik ve klinik çalışmalarda, aprepitant tespiti için güvenle ve rutin olarak kullanılabilir.

Anahtar Kelimeler

Aprepitant , miktar tayini , LC-MS , Subakut sklerozan panensefalit , İnsan plazması

Proje Numarası

This study was funded by Scientific and Technological Research Council of Turkey (TUBITAK), 114S193.

Development of A Rapid and Sensitive LC-MS Method for Determination of Aprepitant Levels in the Plasma of Subacute Sclerosing Panencephalitis Patients

Öz

In this study, a sensitive, selective, rapid, and validated Liquid Chromatography-Mass Spectrometry (LC-MS) method has been developed for routine monitoring of aprepitant concentrations in the blood of patients with subacute sclerosing panencephalitis (SSPE). The developed method was effectively used to detect and monitor potential drug-induced toxicity in SSPE patients. The analyte was extracted from human plasma using liquid-liquid extraction. Chromatographic separation was carried out on a C18 (50 mm x 2.1 mm x 3 µm) column with acetonitrile/0.2% formic acid- water (50/50, v/v)) isocratic mobile phase at a flow rate of 0.40 mL/min. It was studied in mass spectrometry in positive mode by electrospray ionisation technique and aprepitant was detected at 535.20 m/z. The retention time for the aprepitant was 2.70 min, and the total retention time was 4.8 min. The linear concentration range was 0.0125-3.00 µg/mL (r=0.9976), LOD and LOQ values were 0.01 µg/mL and 0.03 µg/mL, respectively. The developed method was successfully used for the determination of aprepitant concentration in plasma samples from SSPE patients. The developed and validated method is selective, sensitive and rapid. It can be safely and routinely used for aprepitant detection in preclinical and clinical studies.

Anahtar Kelimeler

Aprepitant , Determination , LC-MS , Subacute Sclerosing Panencephalitis , Human plasma

Etik Beyan

The study was approved by regional ethical standards committees on human experimentation (26247029-514-04-02).

Destekleyen Kurum

TUBITAK

Proje Numarası

This study was funded by Scientific and Technological Research Council of Turkey (TUBITAK), 114S193.

Teşekkür

The authors thank subacute sclerosing panencephalitis patients and parents.

Kaynakça

• Adel, N. 2017. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies, The American Journal of Managed Care, 16, 259-265.
• Chaitanya, K. K., Sankar, D. G., Israel, D. S., and Narasimha, K., 2013. Validated RP-HPLC method for the quantification of aprepitant in bulk and pharmaceutical dosage forms. Der Pharma Chemica, 5, 39–46
• Chavez-Eng, C. M., Constanzer, M.L., and Matuszewski, B. K., 2004. Simultaneous determination of aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis, 35, 1213–1229 https://doi.og/10.1016/j.jpba.2004.03.020
• Erdoğan, N., Reçber, T., İskit, A. B., Bilensoy, E., Kır, S., Nemutlu, E., 2021. Determination and validation of aprepitant in rat plasma using LC-MS/MS. Bioanalysis, 13, 363–372 https://doi.og/10.4155/bio-2020-0293
• Hesketh, P. J., Grunberg, S. M., Gralla, R., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M.E., Evans, J. K., Beck, K., Reines, S., and Horgan, K. J., 2003. Aprepitant Protocol 052 Study Group J. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group, Journal of Clinical Oncology, 21, 4112–4119 https://doi.og/10.1200/JCO.2003.01.095
• Imre, S., Tero-Vescan, A., Dogaru, M.T., Kelemen, L., Muntean, D. L., Curticapean, A., Szegedi, N., and Vari, C. E. 2019. With or Without Internal Standard in HPLC Bioanalysis. A Case Study. Journal of chromatographic science, 57, 243-248. https://doi.og/10.1093/chromsci/bmy106
• Jafri, S. K., Kumar, R., and Ibrahim, S. H., 2018. Subacute sclerosing panencephalitis—Current perspectives. Pediatric Health, Medicine and Therapeutics, 9, 67–71 https://doi.og/10.2147/PHMT.S126293
• Kara, N., and Demirbaş, A. 2023. Sularda pestisitlerin belirlenmesi için LC-MS/MS ile ekstraksiyonsuz analiz yöntemi. Türk Hijyen ve Deneysel Biyoloji Dergisi, 74, 41-48.
• Makhortova, N. R., Askovich, P., Patterson, C. E., Gechman, L. A., Gerard, N. P., and Rall, G. F., 2007. Neurokinin-1 enables measles virus trans-synaptic spread in neurons. Virology, 362, 235–244 https://doi.og/10.1016/j.virol.2007.02.033
• Manak, M. M., Moshkoff, D. A., Nguyen, L.T., Meshki, J., Tebas, P., Tuluc, F., and Douglas, S.D., 2010. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS, 24, 2789–2796 https://doi.og/10.1097/QAD.0b013e3283405c33
• Mehboob, R., Kurdi, M., Bamaga, A., Aldardeir, N., Nasief, H., Moshref, L. H., Alsinani, T., Rayes, A. O., and Jabbad, R.H., 2021. Substance P/neurokinin-1 receptor, trigeminal ganglion, latency, and coronavirus infection—Is there any link? Frontiers in Medicine, 8, 727593 https://doi.og/10.3389/fmed.2021.727593
• Naito, T., Suzuki, Y., Shibata, K., and Kawakami, J., 2021. Simple liquid chromatography-tandem mass spectrometry method for quantitation of total and free aprepitant and its active N-dealkylated metabolites in human plasma. Therapeutic Drug Monitoring, 43, 422–428
• Nijstad, A. L., Tibben, M. M., Gebretensae, A., Rosing, H., de Vos-Kerkhof, E., Zwaan, C. M., Huitema, A. D. R., and Beijnen, J. H., 2021. Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 1171, 122639. https://doi.og/10.1016/j.jchromb.2021.122639
• Oncel, I., Sancar, M., Konuskan, B., Arioz, F., Tezcan, S., Arman-Kandirmaz, E., Parlak, S., Gumeler, E., and Anlar, B., 2020. Aprepitant in the treatment of subacute sclerosing panencephalitis: a randomized, double-blind, placebo-controlled study. Pediatric Neurology, 110, 59–63 https://doi.og/10.1016/j.pediatrneurol.2020.05.009
• Özçelik, N., Arslan, İ.A., and Şengil, İ. A. 2023. Ambalajlanmış içme sularında akrilamid tayini: LC-MS/MS yöntemiyle doğrudan enjeksiyon çalışması. Gıda ve Su Güvenliği Dergisi, 18, 251-260. PVDLS, R. P., Sumadhuri, B., and Srikanth, M., 2013. Determination of aprepitant in human plasma by using LC-MS/MS with electrospray ionization. Journal of Bioequivalence & Bioavailability, 5, 110–116
• Safwat, A., Helmy, A., and Gupta, A., 2023. The role of substance P within traumatic brain injury and implications for therapy. Journal of Neurotrauma, 40, 1567–1583 https://doi.og/10.1089/neu.2022.0510
• Samia, P., Oyieke, K., Tunje, D., Udwadia-Hegde, A., Feemster, K., Oncel, I., and Anlar, B., 2022. Options in the treatment of subacute sclerosing panencephalitis: implications for low resource areas. Current Treatment Options in Neurology, 24, 99–110 https://doi.og/10.1007/s11940-022-00710-x
• Schirinzi, T., Lattanzi, R., Maftei, D., Grillo, P., Zenuni, H., Boffa, L., Albanese, M., Simonetta, C., Bovenzi, R., Maurizi, R., Loccisano, L., Vincenzi, M., Greco, A., Di Girolamo, S., Mercuri, N. B., Passali, F. M., and Severini, C., 2023. Substance P and prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction. Brain, Behavior, and Immunity, 108, 302–308 https://doi.og/10.1016/j.bbi.2022.12.017
• Tebas, P., Spitsin, S., Barrett, J. S., Tuluc, F., Elci, O., Korelitz, J. J., Wagner, W., Winters, A., Kim, D., Catalano, R., Evans, D. L., and Douglas, S. D., 2015. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS, 29, 931–939 https://doi.og/10.1097/QAD.0000000000000638
• Tebas, P., Tuluc, F., Barrett, J. S., Wagner, W., Kim, D., Zhao, H., Gonin, R., Korelitz, J., and Douglas, S. D., 2011. A randomized, placebo-controlled, double-masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One, 6, e24180 https://doi.og/10.1371/journal.pone.0024180
• Twardy, B. S., Channappanavar, R., and Suvas, S., 2011. Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions. Investigative Ophthalmology & Visual Science, 52, 8604–8613, 2011. https://doi.og/10.1167/iovs.11-8089
• Wenya, X., Wang, T., and Zhou, H., 2018. Substance P and its role in viral infection. International Journal of Clinical and Experimental Medicine, 11, 12946–12955
• Wu, D., Paul, D. J., Zhao, X., Douglas, S. D., and Barrett, J. S., 2009. A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. Journal of Pharmaceutical and Biomedical Analysis, 49, 739–745 https://doi.og/10.1016/j.jpba.2008.12.005
• Bioanalytical method validation 2018. Food and Drug Administration https://www.fda.gov/media/70858/download (Accessed date: 22.11.2024)
• Clinical Trials. Aprepitant injectable emulsion in patients with COVID-19 (GUARDS-1). https://clinicaltrials.gov/study/NCT04470622?cond=NCT04470622&rank=1. (Access date: 13.10.2024)